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ABSTRACT The TATA box-binding protein (TBP) inter-
acts in vitro with the activation domains of many viral and
cellular transcription factors and has been proposed to be a
direct target for transcriptional activators. We have examined
the functional relevance of activator-TBP association in vitro
to transcriptional activation in vivo. We show that alanine
substitution mutations in a single loop ofTBP can disrupt its
association in vitro with the activation domains of the herpes
simplex virus activator VP16 and of the human tumor sup-
pressor protein p53; these mutations do not, however, disrupt
the transcriptional response ofTBP to either activation domain
in vivo. Moreover, we show that a region ofVP16 distinct from its
activation domain can also tightly associate with TBP in vitro, but
fails to activate transcription in vivo. These data suggest that the
ability of TBP to interact with activation domains in vitro is not
directly relevant to its ability to support activated transcription
in vivo.
RNA polymerase II transcription in eukaryotes is controlled
by a diverse range of regulatory proteins that signal the
conserved basal transcriptional machinery to initiate tran-
scription. Transcriptional activators are proposed to function
by directly contacting one or more of the basal factors (re-
viewed in ref. 1), enhancing the rate of basal factor recruitment
to the promoter (2-4) or the rate of promoter clearance and
elongation (5). Although transcriptional activation has been
studied extensively in vitro, little is known of the way in which
the basal factors respond to activators in vivo.
We have previously studied the role played by the TATA
box-binding protein (TBP)-a central component of the basal
transcription factor TFIID-in transcriptional response to a
wide range of activators in human cells (6). We found that TBP
activity in vivo is resistant to single sets of mutations on the
surface of the molecule but is sensitive to specific combinations
of mutations in different regions across the protein. This
pattern of behavior correlates well with the ability of TBP to
associate with the largest TBP-associated factor (TAF) in the
TFIID complex, hTAF11250, suggesting that recruitment of
TBP into TFIID plays a major role in transcriptional activation
in vivo.
Despite the importance of TFIID, however, activators may
have multiple targets among the basal machinery (1), including
TFIIB (3, 7, 8) and TBP itself. Indeed, the acidic activation
domain of the herpes simplex virus transactivator VP16 (9), as
well as the activation (refs. 1 and 10-15 and refs. therein) or
DNA-binding (16-19) domains of at least 25 other transcrip-
tional activators associate directly with TBP in vitro. Further-
more, mutational analyses of activation domains have revealed
a good correlation between the ability of activators to associate
with TBP and to activate transcription both in vitro and in vivo
(10-14, 20), and a mutation in yeast TBP that disrupts
activation domain binding also disrupts activation of transcrip-
tion in vitro (21). However, the in vivo effects of mutations in
TBP that block interaction with activation domains have not
been described.
Here we analyze the relationship between transcription
factor-TBP association in vitro and transcriptional activation in
vivo. We demonstrate that both the VP16 transcriptional
activation domain and the remainder of the protein associate
with TBP in vitro, but only the activation domain activates
transcription in vivo. We also show that point mutations in a
loop connecting a-strands S3' and S4' of human TBP disrupt
association with the VP16 and p53 activation domains in vitro,
but they do not affect transcriptional activation in vivo. We
conclude that the ability of TBP to associate with activation
domains in vitro is neither necessary nor sufficient for tran-
scriptional activation in vivo.
MATERIALS AND METHODS
Plasmid DNA Manipulations. Mutant TBP constructs were
derived by site-directed mutagenesis (22) of the parental
pCGN construct encoding altered-specificity human TBP (6),
designated TBPAS. GAL4-fusion proteins were constructed by
insertion of the appropriate fragments into the Xba I and
BamHI sites of the vector pCGGAL(1-94) (23), provided by
C. Hinkley (Cold Spring Harbor Laboratory). pCGGAL(1-
94)-p53AD was constructed by PCR amplification of sequences
encoding residues 1-73 of human p53 from the vector pBS-p53
(gift of C. Prives, Columbia University, New York) and insertion
of the resulting fragment into pCGGAL(1-94). pCGGAL4-
VP16AAD was constructed by cloning of the Xba I/BamHI
fragment from pCGNVP16AC (ref. 24; kindly provided by R.
Freiman, Cold Spring Harbor Laboratory) into pCGGAL4(1-
94). pCGGAL4-VP16AD (23) was provided by G. Das (Cold
Spring Harbor Laboratory).
For production of recombinant glutathione-S-transferase
(GST)-fusion proteins in Escherichia coli, Xba I/BamHI frag-
ments encoding the activation domains of p53 (residues 1-73)
and VP16 (residues 413-490) were inserted into theXba I and
BamHI sites of pETllcGST (25). pET11cGST-VP16&AD (for-
merly -VP16AC) was a gift from J.-S. Lai (25); pET11cGST-
STOP, carrying an in-frame stop codon immediately after the
GST moiety, was kindly provided by M. Tanaka (Cold Spring
Harbor Laboratory).
Cell Culture and Transfections. The altered-specificity TBP
assay was- performed in transiently transfected HeLa cells
exactly as described (6). Expression of GAL4-fusion proteins
was confirmed by electrophoretic mobility shift analysis of
transfected cell extracts; equivalent levels of expression of all
mutant TBPs were confirmed by Western blot analysis.
"GST-Pulldown" Assays. GST-fusion proteins were ex-
pressed in E. coli by use of the T7 expression system of Studier
et al. (26) and bound to glutathione-agarose (Sigma) as
described (6). After extensive washing in HEMGN buffer (2)
Abbreviations: TBP, TATA box-binding protein; TAF, TBP-associated
factor; GST, glutathione-S-transferase; DBD, DNA-binding domain.
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containing 0.15 M KCl, the amount of each GST-fusion
protein bound to glutathione-agarose was quantitated by
SDS/PAGE, followed by Coomassie blue staining.
35S-labeled wild-type and mutant human TBPAS molecules
were generated by in vitro transcription and translation with
either the TNT coupled transcription/translation system (Pro-
mega) or the standard reticulocyte lysate translation system
(Promega). The synthesis of full-length TBP was quantitated
by SDS/PAGE followed by phosphor imaging (Fuji).
GST-pulldowns were conducted by incubation of equivalent
amounts of 35S-labeled TBP derivatives with 6 gl of GST-beads(carrying 2 Ag of each GST fusion protein) in a final volume
of 20 ,ul. After being mixed at 4°C for 40 min, the beads were
recovered by low-speed centrifugation and washed four times
with 800 ,ul ofHEMGN containing 0.15 M KCl and twice with
800 ,ul of HEMGN containing 0.3 M KCl. The samples were
then placed in SDS/loading buffer and resolved by denaturing
SDS/PAGE, followed by fluorography. Where stated, the
amount of labeled TBPAS bound to the various GST-beads was
quantitated by phosphor imaging.
RESULTS
To probe the functional significance of activator-TBP associ-
ation, we examined the effects of double and triple alanine-
substitution mutations in TBP on both association with acti-
vators in vitro and response to activators in vivo. The TBP
structure, shown in Fig. 1, consists of four a-helices and ten
antiparallel (3-sheets, eight of which make up the concave
DNA-binding surface on the underside of the molecule (28).
We targeted charged residues on the outer surface of TBP,
positioned away from the DNA-binding surface, for mutagen-
esis (Fig. 1; ref. 6). Mutations in helices H2 and Hi', as well
as in loops connecting 13-strands S3/S4 and S3'/S4', were
analyzed because their activity could be monitored in vivo;
TBP molecules carrying the double-alanine substitutions in
helices Hi and H2' (Fig. 1) could not be expressed in HeLa
cells (6).
We initially compared the behavior of two regions of the
herpes simplex virus transactivator VP16: Its acidic activation
domain, designated VP16AD (residues 413-490; ref. 29), and
the remainder of the protein, designated VP16AAD (residues
5-412). VP16,&AD recruits two cellular factors, Oct-1 and HCF,
to herpes simplex virus immediate early gene promoters, forming
a multiprotein complex that in the presence of the VP16 activa-
tion domain stimulates viral transcription (30). We fused these
two regions of VP16 individually to GST sequences and examined
their ability to bind radiolabeled TBP molecules in a GST-
H2 H2'
FIG. 1. Structure of TBP, showing the positions of mutations
analyzed in this study. The diagram depicts a MOLSCRIPT (27) version
of the conserved carboxyl-terminal domain of Arabidopsis thaliana
TBP-2 (28), with the positions of the HI', H2, S3/S4, and S3'/S4'
mutations indicated by filled circles. The positions of the Hl and H2'
mutations, which could not be expressed in HeLa cells, are indicated
by open circles.
pulldown assay. We also fused the VP16 sequences to the
heterologous GAL4 DNA-binding domain (DBD; residues 1-94;
ref. 31) and determined their potential to activate transcription in
vivo from a c-fos reporter construct carrying four synthetic GAL4
binding sites (6). To measure the response of wild-type and
mutant TBPs to these GAL4-fusion proteins, we used a form of
TBP with an altered DNA-binding specificity (TBPAS; ref. 32);
this circumvents the activity of endogenous TBP and allows the
effects of mutations in TBP to be monitored in transient trans-
fection assays in human HeLa cells (6).
The Ability to Associate with TBP in Vitro Is Not Sufficient
for Transcriptional Activation in Vivo. The in vitro association
of GST-VP16AD and GST-VP16AAD with TBP is shown in Fig.
2A. Consistent with previous studies of yeast TBP (9, 14),
approximately 20% of the input human TBPAS protein re-
mained associated with the GST-VP16AD beads (lane 16), a
35-fold higher level than background binding to the GST beads
alone (lane 6). Unexpectedly, GST-VP16&AD also tightly as-
sociated with TBPAS in vitro (lane 11), binding approximately
10% of the input labeled protein. Both VP16AD and VP16A2AD
bound to residues in the conserved carboxyl-terminal core of
TBP (data not shown). Despite binding TBP to similar levels
in vitro, however, the two regions of VP16 displayed markedly
different activation abilities in vivo: GAL4-VP16AAD did not
activate transcription any more than the GAL4 DBD alone
(Fig. 2B, compare lanes 2 and 8), whereas the GAL4-VP16pD
fusion activated transcription more than 1000-fold better than
GAL4 DBD (compare lanes 2 and 14). A GAL4-VP16&AD-
fusion protein has previously been shown to activate transcrip-
tion weakly in mammalian cells (33); the difference in activity
of our GAL4-VP16&AD protein may reflect the smaller region
of GAL4 (residues 1-94 versus 1-147) used in our study.
Whichever the reason, the inactivity of GAL4-VP16&AD de-
scribed here shows that the ability of VP16AAD to associate
with TBP in vitro is not sufficient to achieve transcriptional
activation in vivo.
A Double Amino Acid Substitution in TBP That Disrupts
Association with the VP16 Activation Domain in Vitro Does
Not Affect the Response ofTBP to VP16 Activation in Vivo. We
next examined the ability of the double and triple alanine
substitution mutations on the surface of TBP (Fig. 1) to
interfere with the association between TBP and VP16 in vitro.
As previously described (6), and shown for comparison in Fig.
2B, these mutations have little if any effect on c-fos promoter
activation in response to GAL4-VP16AD in vivo (lanes 14-18);
nor, as expected, do they elicit a response to the transcrip-
tionally inactive GAL4 DBD (lanes 2-6) or GAL4-VP16AAD
proteins (lanes 8-12).
None of these mutations disrupted the in vitro association of
TBPAS with GST-VP16&AD (Fig. 2A, lanes 12-15). Similarly,
three of the mutations-Hi', H2, and 53/54-as well as
alanine substitutions in helices Hi and H2' (Fig. 1; data not
shown) had no more than a 2-fold effect on the association of
TBP with GST-VP16AD (lanes 17-19). In contrast, however,
the S3'/S4' mutation in TBPAS (or wild-type TBP; data not
shown) resulted in less than 5% the wild-type level of associ-
ation with the VP16 activation domain (Fig. 2A; compare lane
16 with lane 20). Disruption of VP16 activation domain
association by the S3'/S4' mutation is probably not the result
of overall disruption of the TBP structure, because this mutant
can associate at wild-type levels with both human TAF1I250
and TFIIB in vitro and is fully active in vivo (ref. 6; see Fig. 2B,
lane 18). These data indicate that (i) the S3'/S4' loop of TBP
is an important site for contact with the VP16 activation
domain and (ii) the ability of TBP to interact with the VP16
activation domain in vitro is not required for transcriptional
activation in vivo.
The Effects ofa Mutation in TBP That Specifically Disrupts
VP16 Activation in Vivo Are Distinct from Its Effects on VP16
Association in Vitro. We have previously described a triple
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FIG. 2. A double-alanine substitution in the S3'/S4' loop of TBP disrupts association with the VP16 activation domain in vitro but does not
affect its response to the VP16 activation domain in vivo. (A) In vitro association ofTBPAs molecules with GST-fusion proteins. 35S-labeled wild-type
(WT) and mutant (Hi', H2, S3/S4, and S3'/S4') TBPAS molecules were tested for association with agarose beads carrying GST sequences alone
(lanes 6-10), or GST-VP16AAD (lanes 11-15) or GST-VP16AD (lanes 16-20) fusion proteins. Ten percent of the input of each labeled TBPAS is
shown for comparison (lanes 1-6). (B) In vivo analysis of GAL4-fusion activators. RNase protection analysis of RNA isolated from HeLa cells
transfected with an altered c-fos T-jTAAA reporter, an a-globin internal control plasmid, an expression construct encoding the TBPAS listed above
each lane, and expression constructs encoding either the GAL4 DBD alone (lanes 1-6), GAL4-VP16ArAD (lanes 7-12), or GAL4-VP16AD (lanes
13-18). The positions of correctly initiated transcripts from the c-fos and a-globin (a) plasmids are indicated. GAL4 activators are present in all
lanes.
combined mutant of TBP-Hl'+S3/S4+S3'/S4'-that re-
sponds poorly to the VP16 activation domain in vivo (10%
wild-type activity) but responds much better (between 40%
and 100% wild-type activity) to all other activation domains
examined (6). Although all three sets of mutations are re-
quired to generate the VP16-specific defect of this TBP, we
were intrigued that one of these mutations, S3'/S4', disrupts
VP16AD binding to TBP in vitro. Because we have observed
extensive redundancy in TBP function in vivo (6), we reasoned
that the effects of disrupting the TBP-VP16 interaction may be
apparent only in the context of other mutations in TBP. We
therefore used the Hi'+S3/S4+S3'/S4' mutant to test this
hypothesis. We first asked whether each individual alanine
substitution in the S3'/S4' mutation-K297A and R299A-
could disrupt association with the VP16 activation domain in
vitro. We then asked what effect these individual substitutions
had when combined with the H1'+S3/S4 double mutation.
This analysis is shown in Fig. 3.
Like the S3'/S4' mutation, the individual K297A and R299A
mutations had little impact on the in vivo response of TBP to
GAL4-VP16AD (Fig. 3B, lanes 4 and 5). Both mutations did,
however, have a significant effect on association with the VP16
activation domain in vitro (Fig. 3A): The K297A mutation
reduced the TBP-VP16ADassociation to approximately 12% of
wild-type levels (lane 3), and the R299A mutation (lane 4)
reduced the association to about 30% of wild-type levels. Thus
the in vitro association ofTBP with the VP16 activation domain
is sensitive to either of two point mutations in a single loop of
TBP.
We next engineered these mutations into the H1'+S3/S4
mutant TBP background. Combining the Hl' and S3/S4
mutations resulted in a reduction in TBP-VP16AD association
to 30% (Fig. 3A, lane 5); this level was reduced to approxi-
mately 10% by addition of either the K297A or R299A single
mutations (lanes 7 and 8). In contrast, addition of the K297A
and R299A mutations to the H1 '+S3/S4 background had no
evident effect on response to GAL4-VP16AD (Fig. 4B, com-
pare lanes 8 and 9 with lane 6). Indeed, it was only when both
the K297A and R299A mutations were combined with the
TBPAS:
S3'/S4'
MUTATION: K29 7A
LR29A
WT+ Hl+S31S4+
-
A 10% Load
GST-VP1 6AD 3 -_AM.__
GST
1 2 3 4 5 6 7 8
B
GAL4-VP1 6AD
abNdI4d imfi c-fos
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FIG. 3. Single point mutations in TBP discriminate between the
effects of reduced TBP-VP16AD association in vitro and reduced
response to VP16AD in vivo. (A) GST-pulldown analysis of the effects
of the K297A and R299A mutations on association of TBPAS with
GST-VP16AD in vitro. These mutations were assayed in the context of
either wild-type TBPAS (lanes 2-4) or H1' +S3/S4 (lanes 6-8) mutant
TBPAS. At the top, + indicates the presence of the particular mutation
listed on the left and - indicates wild-type TBP sequences at that
position. (B) In vivo analysis of the TBP mutants described in A,
examining response to GAL4-VP16AD. Details of the assay are
described in the legend to Fig. 2B. GAL4-VP16AD is present in all
lanes.
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FIG. 4. The S3'/S4' mutation disrupts association of TBP with GST-p53AD in vitro but not response to GAL4-p53AD in vivo. (A) GST-pulldown
analysis of the effects of the Hl', H2, S3/S4, and S3'/S4' mutations on association of TBPAS with GST-p53AD in vitro. Details of the assay are
described in the legend to Fig. 2A. (B) In vivo analysis of the effects of single (lanes 1-6) or combined (7-13) sets of mutations in TBPAS on response
to GAL4-p53AD. GAL4-p53AD is present in all lanes. The positions of correctly initiated c-fos and a-globin transcripts are indicated.
H1'+S3/S4 mutations, resulting in the Hi'+S3/S4+S3'/S4'
combination, that a significant reduction in GAL4-VP16AD
transactivation was observed (lane 7). The finding that both
mutations in the S3'/S4' loop are required for disruption of
VP16 activation in vivo, whereas each mutation separately is
sufficient to disrupt VP16AD association in vitro, argues that
disruption of the VP16AD-TBP association does not contribute
to the activator-specific transcriptional defects of the Hi' +S3/
S4+S3'/S4' mutation.
The S3'/S4' Mutation Also Disrupts Association of TBP
with the Activation Domain of p53 in Vitro but Does Not Affect
Response to p53 in Vivo. We next examined the functional
significance of association between TBP and the acidic acti-
vation domain from the human tumor suppressor protein p53
(pS3AD: residues 1-73; ref. 34). We fused the p53 activation
domain to both GST and GAL4 sequences and then compared
association with TBP in vitro with activation in vivo, as shown
in Fig. 4. Consistent with previous reports (34-37), the p53
activation domain both bound wild-type TBPAS in vitro (Fig.
4A, lane 1) and activated transcription to high levels in vivo
(Fig. 4B, lane 2). Like transcriptional activation by all activa-
tors examined (6), activation by GAL4-p53AD was not signif-
icantly affected by any of the single sets of mutations in TBP
(Fig. 4B, lanes 3-6). This pattern was not true of TBP
association in vitro, however, because the S3'/S4' mutation
(Fig. 4A, lane 5) disrupted binding of TBPAs to GST-p53AD.
The same mutation in TBP therefore disrupts association with
both the VP16 and p53 activation domains, suggesting that
these two activation domains interact with TBP through
similar interfaces. Moreover, the TBP-p53AD association can
be disrupted without having an impact on transcriptional
activation in vivo, demonstrating that the ability of the p53
activation domain to interact directly with TBP in vitro is not
required for transcriptional activation in vivo.
To contrast the activity of the acidic p53 activation domain
with that of VP16, we examined the response of several
multiply mutant forms of TBP to GAL4-pS3AD in vivo. As
observed with all activators (6), combining the H2 and S3'/S4'
mutations reduced response to GAL4-pS3AD in vivo to 10% of
wild-type levels (Fig. 4B, compare lanes 8 and 9). All other
double-mutant TBP molecules, regardless of whether they
carried the S3'/S4' mutation, were reduced to 50% for re-
sponse to GAL4-p53AD (compare lane 8 with lanes 10-12).
Remarkably, however, the HI' +S3/S4+S3'/S4' combination,
which is reduced to approximately 10% for response to GAL4-
VP16AD (Fig. 3), showed only the same reduction to 50% for
response to GAL4-p53AD (Fig. 4B, lane 13). This result
demonstrates that VP16 and p53, two acidic activators which
display many structural and functional similarities-including
potency of transactivation, association with TFIIH in vitro (13),
association with TBP in vitro, and sensitivity to the S3'/S4'
mutation-use TBP in different ways to achieve transcrip-
tional activation in vivo.
DISCUSSION
We have investigated the importance of activator-TBP asso-
ciation in vitro for transcriptional activation in vivo. We found
that not only the VP16 activation domain but also the remain-
der of the protein-which does not activate transcription
effectively in vivo-associates well with TBP in vitro. We also
found that mutations in a single loop of TBP disrupt its
association with the activation domains of VP16 and p53 but
do not affect its ability to support activated transcription in
vivo. These findings raise the possibility that direct contact of
TBP by these activation domains, and perhaps others, is not
involved in the transcriptional activation process in vivo.
There are many explanations of how the VP16-TBP and
p53-TBP interactions could be disrupted in vitro without
commensurate effects on transcriptional activation in vivo.
First, the interaction measured between activators and TBP in
vitro may be irrelevant to transcriptional activation, and instead
may reflect forced interactions between two partially compat-
ible proteins under nonphysiological conditions. Mutations in
activation domains may therefore disrupt both interaction with
TBP in vitro and transcriptional activation in vivo not because
they destroy a specific interaction surface, but rather because
they disrupt the overall structural integrity of the activation
domain. A second possibility is that binding of the VP16 and
p53 activation domains to the S3'/S4' mutant TBP, which is
defective in vitro, may still occur in vivo at levels sufficient to
achieve transcriptional activation. Third, activators such as
VP16 and p53 may be able to activate transcription through
multiple pathways, in which case redundancy may mask the
effects of disrupting a direct activation domain-TBP interac-
tion. Finally, direct activation domain-TBP interactions may
be important for transcriptional activation in promoter con-
texts other than the one assayed here. For example, in certain
contexts, activators may stimulate transcription by interacting
directly with the S3'/S4' loop of TBP that we have shown is
critical for interaction with activation domains in vitro.
An alternative possibility, however, that would also explain
how activators such as VP16 can interact with many different
basal factors (reviewed in ref. 1) is that a structure similar to
the S3'/S4' loop of TBP is shared among the basal factors. In
this model, the association of free TBP with activation domains
does not reflect an extant transcriptional process, but rather is
a consequence of how the basal transcriptional machinery
evolved.
For example, during evolution, genes encoding basal factors
may have arisen by duplication, resulting in common structural
motifs being shared among the basal factors. Perhaps TBP-an
ancient basal factor (38)-once not only was involved in
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promoter recognition (i.e., through the TATA box) but also
was a direct target for transcriptional activators. Subsequently,
gene duplication may have allowed some TBP functions (e.g.,
direct activator interaction) to be performed by separate basal
factors, which interact with activators but do not recognize
promoters directly. Through evolution, therefore, TBP may no
longer be generally a direct target of transcriptional activators,
but instead has become incorporated into multiprotein com-
plexes such as TFIID (39) in which TAFs are the direct targets.
We suggest that it is the interaction between TBP and the
largest human TAF, hTAF11250, that both preserves the ability
of TBP to interact with activation domains in vitro and blocks
the direct activator-TBP interaction in vivo. TBP interacts with
hTAF11250 at multiple points across its surface, including the
S3'/S4' loop (6). The S3'/S4' mutation alone, however, is not
sufficient to disrupt either the TBP-hTAF,1250 interaction in
vitro or transcriptional activation in vivo; disruption of both
these activities requires additional mutations in other regions
of TBP (6). The structure of the S3'/S4' loop of TBP may thus
be conserved not for interaction with activators but rather for
interaction with factors such as hTAF11250, which subsequently
blocks activators from interacting directly with TBP by mask-
ing the S3'/S4' loop.
In summary, the idea that a common structural motif in
basal factors is involved in the protein-protein interactions
that regulate transcription provides an explanation of why so
many transcription factors can interact directly with TBP and
with other basal factors as well. Additionally, the model
reinforces the importance of examining activator-basal factor
interactions from the point of view of both partners. If
common or related motifs are used in activator-target inter-
actions, then examination of the effects of mutations only in
activation domains is not sufficient to determine which of the
multitude of interactions demonstrated in vitro are directly
relevant to transcriptional activation in vivo.
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